Micromedic: We will begin a larger trial at several medical centers in Israel and the US.
Micromedic Technologies Ltd. (TASE:MCTC) reports 90% sensitivity in a trial for its diagnostic biomarker kit for breast and ovarian cancer. The kit was developed at Hadassah Medical Organization in Jerusalem by a team headed by Dr. Asher Salmon. Micromedic said that, in view of the results, it would begin a larger trial at several medical centers in Israel and the US.
Source: article de Gali Weinreb @ Globes
Anti Boycott Israel Blog: cancer du sein